- Published at
- by gurufocus.com
positive
positive
Regeneron (REGN) Target Price Cut by Baird, Neutral Rating Maintained | REGN Stock News
Investment firm Baird has adjusted its price target for Regeneron Pharmaceuticals (REGN), reducing it from $759 to $652 while maintaining a Neutral rating for t